Saturday, 30 September 2017

Giving inmates tablet computers designed to streamline Allen County Jail operations, reduce inmate problems

Most Allen County Jail inmates now will receive use of a personal tablet computer, which will give them access to documents and materials the jail legally must provide and allow them to work on rehabilitating themselves, read religious scripture or ebooks, and make phone calls or send short messages to people outside the jail.

The Inspire Inmate Communications Devices are provided at no cost to taxpayers and will be given to inmates as an incentive for good behavior, Allen County Sheriff David Gladieux said in a news release.

Other correctional facilities that have implemented similar programs have reported significant reductions in inmate assaults on jail officers and other inmates as well as a decrease in inmate suicide attempts, the news release said.

Currently, more than 700 Allen County Jail inmates have a tablet assigned to them, the news release said. The sheriff's department partnered with Global Tel Link to provide the tablets.

"This decision was not taken lightly, as the sheriff's intention is not to pamper inmates or make their stay more enjoyable," the news release said.

Providing inmates with paperless access to materials the jail legally must provide will reduce strain on jail employees and resources and also will minimize the risk of possible lawsuits, the news release said.

Tablets won't be provided to inmates who have destroyed one previously, have a history of destroying jail property or who are assessed as too mentally ill to be responsible for a tablet, the news release said.

The only free apps on the tablet will be for documents the jail most provide access to and for a calculator, the news release said.

Many other features available on the tablets will be sold on a subscription basis, with rates available in seven-day, 14-day and 30-day options, the news release said. The subscriptions will cover services such as music, games and ebooks.

Prices range from $1.49 plus tax for a seven-day ebooks subscription to $24.99 plus tax for a 30-day music subscription, the news release said.

The messaging feature will be a "simplified and restricted form of email," the news release said. Each message, which can contain as many as 2,000 letters and characters, costs the inmate 25 cents, no matter whether the message is sent or received.

A person outside the jail must initiate the messaging contact with inmate by setting up an account at www.connectnetwork.com, the news release said.

In the future, friends and family will be able to send photos and 15-second videos to their family member or friend in jail at a cost of 25 cents per photo and $1 for each video clip, the news release said. The photos and video clips will be reviewed by jail staff before the inmate can receive them. Inmates won't be able to send out photos or videos.The phone calling feature on the tablets operates just like the wall phones at the jail and will carry the same costs and restrictions, the news release said.

In the future, the tablets possibly may offer movie streaming, commissary ordering, news feeds and video visitation, the news release said.


Source: Giving inmates tablet computers designed to streamline Allen County Jail operations, reduce inmate problems

Thursday, 28 September 2017

Google’s new app lets parents turn old Android tablets into kid-friendly devices

Google's Family Link app lets parents hand down their old Android gadgets to their kids without worrying about what they could end up downloading from the Play Store or finding online. They just have to create a Google account for their kids and download the app, which went public today. Until now, parents had to request an invite and hope that Google followed up.

Family Link allows parents to approve or block apps that their kids want to download from the Play Store, monitor their screen time and the apps they're accessing, set device time limits, and remotely lock their kid's device for bedtime or studying.

Google is directly targeting Amazon and its kid-friendly Fire tablets with Family Link. Amazon's tablets always let parents set screen time limits, and it recently began letting parents retrieve more granular data on the apps their kids are using and even the books and websites they're accessing. It also launched a new parent-oriented dashboard in April.

Google doesn't seem to readily give parents that kind of access through Family Link, and it says some messaging apps and music players won't be tracked completely. Still, parents likely have old Android phones and tablets they'd like to pass down to their kids, as opposed to having to buy a whole new kid-oriented tablet. Google is now giving them that option without the risk of their kids running rampant on the internet without any supervision.

The app is available for kids so long as they're using a Android device that runs Nougat and higher. Certain devices running Marshmallow work, too. Parents can run Family Link on an Android device running Kit Kat or higher or an iPhone running iOS 9 or higher.


Source: Google's new app lets parents turn old Android tablets into kid-friendly devices

Wednesday, 27 September 2017

YouTube TV is finally available on select Android tablets

When YouTube TV — the live TV streaming service — isn't expanding to new markets, they're busy bringing more Android users into the fold. As tweeted by the YouTube TV account, the service is now available on select Android tablets. Just download the app you'll be streaming on a bigger, more easily viewable display.

Originally announced in February of this year, YouTube TV only went live in select markets back on April 5th. At the time, the 4 major networks were covered along with around 30 cable channels but even then, markets were limited. YouTube Live added 14 new markets last month, with the promise of 17 new markets in the coming weeks (to see the full list, click here).

So, now that Android smartphones and tablets are covered — what about new platforms like Android TV and Roku? It seems that too is also being worked on, but the YouTube TV team wouldn't commit to any sort of release schedule.

Curious to see how YouTube TV compares against competing services? Check out our comparison post linked below.

YouTube TV vs PlayStation Vue vs Sling TV vs DirecTV Now

Auto-load comments: Off On


Source: YouTube TV is finally available on select Android tablets

Tuesday, 26 September 2017

Global Orally Disintegrating Tablets Market, Is Expected to Grow 15.7% by 2025

ODT mini tablets are the latest innovation in the drug class segment, and these combine the convenience of solid dosage forms with increased stability to enable ease of administration, especially in pediatric use. A rising awareness of the benefits of administering orally disintegrating tablets is fueling revenue growth of the global orally disintegrating tablets market.

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 09/26/2017 -- Strategic shift from solid dosage forms to orally disintegrating tablets positively impacting market revenue growth

In line with a World Health Organization directive, pharmaceutical companies across the world are making a calculated move from solid dosage forms to orally disintegrating tablets, mainly due to increased acceptance of orally disintegrating tablets (ODT) among patients of diverse age groups. Orally disintegrating tablets are used by physicians to provide accurate dose combinations to patients. ODT mini tablets are the latest innovation in the drug class segment, and these combine the convenience of solid dosage forms with increased stability to enable ease of administration, especially in pediatric use. A rising awareness of the benefits of administering orally disintegrating tablets is fueling revenue growth of the global orally disintegrating tablets market.

Request Free Sample Report : http://www.mrrse.com/sample/3422

Opportunity assessment by drug class

Manufacturers in the orally disintegrating tablets market are leveraging advanced techniques to manufacture orally disintegrating tablets and are thereby looking to tap into the hitherto untapped market opportunities. There is a greater acceptance of this drug class over conventional solid dosage forms among patients of different age groups and this presents new market opportunities for manufacturers. Further, manufacturers of ODT are taking advantage of product life cycle extension by launching their drugs in different formulations. Also, a high penetration among end users in developed countries will boost the global demand for ODT in the foreseeable future. Owing to technological advancements, manufacturers are focusing on increasing the applicability of ODT technology to different therapeutic areas. This factor is likely to further augment revenue growth of the orally disintegrating tablets market during the forecast period.

Anti-Psychotics drug class to emerge market leader by 2025 end

Among the drug class category in the orally disintegrating tablets market, the Anti-Psychotics drug class segment is likely to beat the other segments in terms of market value share by the end of the forecast period. From a market value share of about 15% estimated to be held in 2017, the Anti-Psychotics segment will account for about 20% market share by the end of 2025, leaving all segments behind. A market value of roughly US$ 1.7 Bn for Anti-Psychotics drugs is estimated in 2017 and this will increase to about US$ 5.6 Bn by the end of 2025, registering an impressive CAGR of 15.7% during the forecast period – the highest among all the drug class segments. The Anti-Psychotics drug class segment dominated the global orally disintegrating tablets market in revenue terms in 2016 and this trend is projected to continue throughout the forecast period. The Anti-Epileptics drug class segment is expected to be the second most lucrative segment in the global orally disintegrating tablet s market, recording a market attractiveness index of 1.4 during the forecast period. The Anti-Epileptics drug class segment will hold a market value share of just under 13% by the end of 2025.

Browse Full Report With TOC : http://www.mrrse.com/orally-disintegrating-tablet-market

Trends in ODT drug class witnessed across different regions

North America: Advancements in improved oral protein delivery technology through ODT will promote the adoption of protein and peptide based therapeutics. ODT in the North America healthcare market are manufactured using patented technologies such as fine particle coating or adding sweeteners into the tablet matrix for taste making, granulation, spray-drying, freeze-drying and molding. The flexibility of orally disintegrating tablets allows molecules of a wide variety of doses and chemical characteristics to be incorporated into an ODT.

Latin America: Manufacturers of ODT in Latin America are focused on innovations such as controlled ODT drug release by changing their excipients. ODT technology is applicable in a wide range of therapeutic agents including generics, thereby adding value, i.e. 'super generics' for veterinary or human applications. Manufacturers in Latin America are leveraging ODT technology to strengthen their product portfolio through product line extensions.

Europe: Companies in the Europe market are adopting nanocrystal technologies to manufacture highly potent and hazardous material as these technologies help reduce the number of steps such as granulation, blending, and tableting. The nanocrystal technology has been patented by Elan Corporation Plc (acquired by Perrigo Company plc).

About MRRSEMarket Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact State Tower90, State StreetSuite 700Albany, NY - 12207United StatesTelephone: +1-518-730-0559Email: sales@mrrse.com

Google+: https://plus.google.com/u/0/109558601025749677847/postsLinked in: https://www.linkedin.com/company/mrrseTwitter: https://twitter.com/MRRSEmrrse

For more information on this press release visit: http://www.sbwire.com/press-releases/global-orally-disintegrating-tablets-market-is-expected-to-grow-157-by-2025-870390.htm


Source: Global Orally Disintegrating Tablets Market, Is Expected to Grow 15.7% by 2025

Monday, 25 September 2017

Razer Plans To Release A Mobile Gaming Device This Year

Gaming laptop maker Razer has confirmed that it will be releasing a new mobile device that's dedicated to gaming. Details on the upcoming Razer mobile gaming device are scarce, but the company is planning to release it before the the end of 2017.

"I can say that we are coming up with a mobile device specifically geared towards gamers and entertainment," Razer CEO Min-Liang Tan told CNBC's Managing Asia. "We are hoping to have it come by the end of the year, so that's something we're working on."

Rumors of a new Razer mobile gaming device have been circulating for quite some time now. Back in July, Bloomberg reported that Razer was developing its own mobile phone that would cater to gamers. The company is also aiming for an initial public offering (IPO) in Hong Kong later this year, which could value Razer at as much as $5 billion.

Razer's CEO was a little bit vague on when the company's new mobile gaming device will be released, and he did not give out other details on what it would actually be. It's very likely that the fate of its new device might hinge on the success of the company's planned IPO, as pointed out by Android Authority.

"We would love to have that war chest to allow us to invest in R&D. We are known to have disrupted many industries," Tan said when he briefly discussed Razer's planned IPO. "We're the first in the gaming peripherals side of things, we were first when we invented the first true gaming laptop, we've gone on to provide one of the largest software platforms for gamers. Having that war chest from the IPO would allow us to do all that and much more. And that's what we want to continue doing: to make cool products."

Tan mentioned that Razer's new mobile device won't only be for gamers, but it will also be for entertainment. When asked on whether Razer will soon become an entertainment company, the CEO responded by saying that "we already are," according to Ars Technica. He pointed out that gaming's already the largest segment of entertainment and that the only things left that they haven't explored are movies and music.

Last year, Razer acquired THX, a company that's known for developing high fidelity audiovisual standards for movie and home theaters. Razer could definitely use THX's collection of IPs and engineers to develop a mobile device that can offer a unique audiovisual experience for watching TV shows and movies.

Additionally, Razer has acquired console maker Ouya and the smartphone maker Nextbit. Razer already has everything it needs to develop its own gaming and entertainment mobile device, the only concern now is if it's going to be a tablet or a smartphone.

Razer already came out with a gaming tablet, called Razer Edge, back in 2013. The tablet allowed users to attach additional controller accessories on the sides to turn it into a handheld gaming system. The concept is very reminiscent of the Nintendo Switch, which is already seeing huge success since it was first released this past March.

Whatever Razer is planning, it definitely would be interesting to see what the company has in store for its fans. A Razer smartphone would be a surprise, but a tablet form factor seems like the best approach. That is of course if Razer's IPO later this year is successful.

Razer EdgeRazer already released a gaming tablet with the Razer Edge back in 2013, but the company is also planning to release a new mobile gaming device before the end of 2017. Photo: Razer


Source: Razer Plans To Release A Mobile Gaming Device This Year

Sunday, 24 September 2017

Oxymorphone HCl Extended-Release Tablets

Indications for Oxymorphone HCl Extended-Release Tablets:

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Limitations Of use:

Not for use as an as-needed (prn) analgesic. Use only if alternative treatment options (eg, non-opioid analgesics, immediate-release opioids) are ineffective, not tolerated, or otherwise inadequate to provide sufficient management of pain.

Adult:

Use lowest effective dose for shortest duration. Individualize. Take on empty stomach. May give Opana as needed on an every 4–6hrs schedule; oxymorphone ext-rel tab is given on a continuous basis every 12hrs. ≥18yrs: Opioid-naive: Opana: 10–20mg every 4–6hrs as needed. Ext-rel tab: Swallow whole; 5mg every 12hrs, titrate by 5–10mg every 12hrs every 3–7 days; if breakthrough pain occurs: adjust dose or use a small-dose rescue medication (eg, immediate-release oxymorphone). Converting from Opana to ext-rel tab: Give half the total daily Opana dose as oxymorphone ext-rel every 12hrs. Conversion from other opioids: see full labeling. Mild hepatic impairment, renal impairment (CrCl <50mL/min), or elderly (≥65yrs): opioid-naive: initiate with 5mg dose; opioid-experience: initiate at 50% lower than normal starting dose and titrate slowly. Concomitant other CNS depressants: initiate at ⅓–½ of usual starting dose and monitor. Withdraw gradually by 25–50% every 2–4 days.

Children:

<18yrs: not established.

Contraindications:

Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus. Moderate-to-severe hepatic impairment.

Warnings/Precautions:

Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Accidental exposure may cause fatal overdose (esp. in children). COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Drug and alcohol abusers. Renal or hepatic impairment. ER tabs: difficulty in swallowing or at risk for underlying GI disorders (eg, esophageal or colon cancer); consider other analgesics. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Labor & delivery, nursing mothers: not recommended.< /p> Interactions:

Avoid alcohol or alcohol-containing products. Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and precipitate withdrawal symptoms. May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergic s. May be potentiated by cimetidine. May increase serum amylase.

See Also:

OPANA

Pharmacological Class:

Opioid agonist.

Adverse Reactions:

Nausea, constipation, dizziness, somnolence, vomiting, pruritus, headache, sweating increased, dry mouth, sedation, diarrhea, insomnia, fatigue, appetite decreased, abdominal pain; respiratory depression, severe hypotension, syncope, hypersensitivity, angioedema.

Note:

Formerly known under the brand name Opana ER.

Metabolism:

Hepatic.

Elimination:

Renal, fecal.

REMS:

YES

Generic Availability:

YES

How Supplied:

Ext-rel tabs—contact supplier; Opana—100


Source: Oxymorphone HCl Extended-Release Tablets

Saturday, 23 September 2017

Zydus receives final approval from USFDA for Amlodipine and Olmesartan Medoxomil tablets

Sep 23, 2017 07:33 PM IST | Source: Moneycontrol.com

Zydus receives final approval from the USFDA for Amlodipine and Olmesartan Medoxomil TabletsSource : BSE
Source: Zydus receives final approval from USFDA for Amlodipine and Olmesartan Medoxomil tablets

Friday, 22 September 2017

Razer Plans To Release A Mobile Gaming Device This Year

Gaming laptop maker Razer has confirmed that it will be releasing a new mobile device that's dedicated to gaming. Details on the upcoming Razer mobile gaming device are scarce, but the company is planning to release it before the the end of 2017.

"I can say that we are coming up with a mobile device specifically geared towards gamers and entertainment," Razer CEO Min-Liang Tan told CNBC's Managing Asia. "We are hoping to have it come by the end of the year, so that's something we're working on."

Rumors of a new Razer mobile gaming device have been circulating for quite some time now. Back in July, Bloomberg reported that Razer was developing its own mobile phone that would cater to gamers. The company is also aiming for an initial public offering (IPO) in Hong Kong later this year, which could value Razer at as much as $5 billion.

Razer's CEO was a little bit vague on when the company's new mobile gaming device will be released, and he did not give out other details on what it would actually be. It's very likely that the fate of its new device might hinge on the success of the company's planned IPO, as pointed out by Android Authority.

"We would love to have that war chest to allow us to invest in R&D. We are known to have disrupted many industries," Tan said when he briefly discussed Razer's planned IPO. "We're the first in the gaming peripherals side of things, we were first when we invented the first true gaming laptop, we've gone on to provide one of the largest software platforms for gamers. Having that war chest from the IPO would allow us to do all that and much more. And that's what we want to continue doing: to make cool products."

Tan mentioned that Razer's new mobile device won't only be for gamers, but it will also be for entertainment. When asked on whether Razer will soon become an entertainment company, the CEO responded by saying that "we already are," according to Ars Technica. He pointed out that gaming's already the largest segment of entertainment and that the only things left that they haven't explored are movies and music.

Last year, Razer acquired THX, a company that's known for developing high fidelity audiovisual standards for movie and home theaters. Razer could definitely use THX's collection of IPs and engineers to develop a mobile device that can offer a unique audiovisual experience for watching TV shows and movies.

Additionally, Razer has acquired console maker Ouya and the smartphone maker Nextbit. Razer already has everything it needs to develop its own gaming and entertainment mobile device, the only concern now is if it's going to be a tablet or a smartphone.

Razer already came out with a gaming tablet, called Razer Edge, back in 2013. The tablet allowed users to attach additional controller accessories on the sides to turn it into a handheld gaming system. The concept is very reminiscent of the Nintendo Switch, which is already seeing huge success since it was first released this past March.

Whatever Razer is planning, it definitely would be interesting to see what the company has in store for its fans. A Razer smartphone would be a surprise, but a tablet form factor seems like the best approach. That is of course if Razer's IPO later this year is successful.

Razer EdgeRazer already released a gaming tablet with the Razer Edge back in 2013, but the company is also planning to release a new mobile gaming device before the end of 2017. Photo: Razer


Source: Razer Plans To Release A Mobile Gaming Device This Year

Thursday, 21 September 2017

Toro Releases AquaFlowâ„¢ Tablet App for On-the-Go Field Designs

EL CAJON, Calif.--(BUSINESS WIRE)--

Toro is pleased to announce the release of a tablet app for its popular drip irrigation design software, AquaFlow™, available for both Apple and Android tablet devices. This innovative solution greatly simplifies the drip irrigation design process and improves accessibility to otherwise complicated drip irrigation design information.

"The all-new AquaFlow tablet app creates a more powerful and convenient user experience, as it's fully integrated across all software platforms – from tablet to desktop," says Inge Bisconer, technical marketing and sales manager for Toro. "Users can now seamlessly access designs created on-the-go in the field, including lateral, submain and flushing information, with their desktop devices later."

With the new AquaFlow tablet app, users can quickly and easily choose laterals and submains, and instantly view results in tables, graphs and a visually friendly, color-coded uniformity map. AquaFlow even allows users to weigh various design options with one-click, to easily compare one lateral choice versus another. "Using this feature, users can quickly compare, for example, the emission uniformity (EU) of the design using ordinary drip tape versus a FlowControl drip tape," continues Bisconer. "With higher EU's, farmers can become better irrigators to help increase yields, reduce farm inputs and improve sustainability."

In addition to the tablet app, Toro is pleased to announce the release of AquaFlow 4.1's desktop platform upgrade that provides faster performance and a smaller local installation than previous versions and compatibility with browser improvements. In addition, AquaFlow 4.1 helps users remain within Toro emission device operating specifications.

"For nearly two decades, Toro has continuously upgraded the AquaFlow drip irrigation design program to keep pace with changes in technology, and market demands," says Phil Burkart, vice president of The Toro Company's Irrigation and Lighting Businesses. "The AquaFlow tablet app and AquaFlow 4.1 platform upgrade are the latest innovations to optimize drip irrigation performance everywhere."

AquaFlow's tablet app can be downloaded onto the user's Apple or Android tablet device from the Apple or Google storefronts, and AquaFlow's new desktop vers ion 4.1 may be downloaded from Toro's website. Users must login (or register if they are a first-time user) using their email address and password. Upon logging in, users may then configure a drip irrigation system design on a crop block by entering: 1. Field dimensions; 2. Slope(s) and system pressure; and, 3. Drip/micro laterals and submain pipes from hundreds of available options. Additional unique programming features include: unlimited entry of slopes and telescoping submains, auto-positioning of submain position and inlet, and Spanish and metric options.

To learn more about AquaFlow, visit http://driptips.toro.com/tag/aquaflow/

About The Toro CompanyThe Toro Company (TTC) is a leading worldwide provider of innovative solutions for the outdoor environment including turf, snow and ground engaging equipment, and irrigation and outdoor lighting solutions. With sales of $2.4 billion in fiscal 2016, Toro's global presence extends to more than 90 countries. Through constant innovation and caring relationships built on trust and integrity, Toro and its family of brands have built a legacy of excellence by helping customers care for golf courses, landscapes, sports fields, public green spaces, commercial and residential properties and agricultural fields. For more information, visit www.toro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170911005102/en/


Source: Toro Releases AquaFlow™ Tablet App for On-the-Go Field Designs

Wednesday, 20 September 2017

3,700-Year-Old ‘Mystery’ Babylonian Stone Tablet Is Translated

A 3,700-year-old Babylonian tablet was recently translated and might rewrite the history of math, suggesting that trigonometry may have been developed before the ancient Greeks.

The researchers said the tablet proves that the Babylonians developed trigonometry some 1,500 years prior to the Greeks.

Dr Daniel Mansfield with the Plimpton 322 Babylonian clay tablet in the Rare Book and Manuscript Library at Columbia University in New York. (UNSW/Andrew Kelly)

Dr. Daniel Mansfield with the Plimpton 322 Babylonian clay tablet in the Rare Book and Manuscript Library at Columbia University in New York. (Andrew Kelly/UNSW)

The tablet, called Plimpton 322, was found in Southern Iraq around the turn of the last century. American archaeologist and diplomat Edgar Banks, the inspiration for Indiana Jones discovered the tablet.

As the Telegraph noted:

However unlike today's trigonometry, Babylonian mathematics used a base 60, or sexagesimal system, rather than the 10, which is used today. Because 60 is far easier to divide by three, experts studying the tablet, found that the calculations are far more accurate.

"Our research reveals that Plimpton 322 describes the shapes of right-angle triangles using a novel kind of trigonometry based on ratios, not angles and circles," Dr. Daniel Mansfield of the School of Mathematics and Statistics at the University of New South Wales Faculty of Science, said in a university news release. "It is a fascinating mathematical work that demonstrates undoubted genius. The tablet not only contains the world's oldest trigonometric table; it is also the only completely accurate trigonometric table, because of the very different Babylonian approach to arithmetic and geometry."

He added that what the tablets contained was a "huge mystery until now."

Plimpton 322: The world's first trigonometric table, (Rare Book and Manuscript Library, Columbia University.)

Plimpton 322: The world's first trigonometric table, (Rare Book and Manuscript Library, Columbia University.)

"Plimpton 322 was a powerful tool that could have been used for surveying fields or making architectural calculations to build palaces, temples, or step pyramids," he said.

The Greek astronomer Hipparchus, who lived around 120 B.C., has been regarded as the father of trigonometry.

"Plimpton 322 predates Hipparchus by more than 1,000 years," said UNSW associate professor Norman Wildberger. "It opens up new possibilities not just for modern mathematics research, but also for mathematics education. With Plimpton 322 we see a simpler, more accurate trigonometry that has clear advantages over our own."

Their findings were published in Historia Mathematica.


Source: 3,700-Year-Old 'Mystery' Babylonian Stone Tablet Is Translated

Tuesday, 19 September 2017

Glenmark Pharma gets ANDA approval for Nitroglycerin Sublingual tablets

Sub: Glenmark Pharmaceuticals receives ANDA approval for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Source : BSE


Source: Glenmark Pharma gets ANDA approval for Nitroglycerin Sublingual tablets

Saturday, 16 September 2017

Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets

HERTFORDSHIRE, England and PITTSBURGH, Sept. 14, 2017 / / -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy (1).  Mylan's subsidiary, Mylan Laboratories Limited, received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is a generic version of Allergan's Minastrin® 24 FE Tablets.

Mylan (PRNewsfoto/Mylan N.V.)

The launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, further strengthens Mylan's women's healthcare portfolio, one of 10 therapeutic franchise priority areas for the company. From cancer and hypothyroidism, to cardiovascular disease and diabetes, Mylan offers a vast suite of medicines to help women manage a multitude of health conditions.

Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, had U.S. sales of approximately $346.9 million for the 12 months ending July 31, 2017, according to QuintilesIMS Health.

Currently, Mylan has 225 ANDAs pending FDA approval representing approximately $101 billion in annual brand sales, according to QuintilesIMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $43.5 billion in annual brand sales, for the 12 months ending December 31, 2016, according to QuintilesIMS Health. Currently, one out of every 13 prescriptions filled in the U.S. – brand-name or generic – is a Mylan product.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately

50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com.

(1) Women over 35 years old who smoke should not use Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use.

For further information: CONTACTS: Nina Devlin (Media), 724.514.1968; Melissa Trombetta (Investors), 724.514.1813


Source: Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets

Friday, 15 September 2017

ReMarkable tablet review

A low-power, no-frills tablet that mimics the look and feel of real paper sounds almost too good to be true, but that's startup ReMarkable's sales pitch. The eponymous ReMarkable tablet's custom-designed screen lets you doodle, sketch, and write just like the Microsoft Surface Pro or Apple iPad Pro. But unlike most other stylus-touting tablets on the market, the ReMarkable doesn't suffer from screen glare, lasts days without needing to recharge, and syncs seamlessly with your PC and phone — in theory, that is.

After spending a little more than two weeks with the ReMarkable tablet, we can confidently say that it's the foundation for something great. But like any first-generation technology, not everything about the ReMarkable tablet is as well-executed — or remarkable — as it could be.

Large but lightweight

The ReMarkable is a little larger than the picture on the box lets on, but it's also surprisingly lightweight.

The 10.3-inch screen's measurements (6.9 by 10.1 by 0.26 inches) put the ReMarkable tablet within striking distance of Amazon's Kindle Fire HD 10 (12.04 by 8.96 by 0.27 inches). But when it comes to the overall heft of the thing, it's no contest between the ReMarkable and behemoths like Apple's iPad. The ReMarkable weighs in at 0.77 pounds, or almost a third of a pound lighter than the iPad Pro 10.5 (1.03 pounds).

That makes it really portable. I took to carrying it around one-handed and balancing it on my lap like a legal notepad, as well as stowing it between books on my desk. It's thin enough to squeeze in a crowded book bag or backpack, but I can't attest to its durability — the ReMarkable's exposed screen made me a little wary of trying.

In terms of aesthetics, the ReMarkable tablet keeps it simple. It has a shiny, silver-brushed backplate, with white plastic trim that stretches the length and width of the tablet's screen. An oblong button on the top switches between the tablet's sleep modes and powers it on and off, while three (slightly wobbly) square-shaped buttons on the front handle basic software navigation.

Underneath the plastic housing is the ReMarkable tablet's guts: A 1 GHz ARM A9 CPU, 512MB of RAM, a 2.4GHz/5GHz Wi-Fi chip, and 8GB of internal memory that can store about 100,000 pages of notes.

It's not quite like paper, but there's resistance and texture akin to a really thin sheet of notebook paper.

But the true innovation is the screen. ReMarkable calls it a Canvas display, and if you've ever used a Kindle ebook reader, you'll recognize it right away. The technology is called E Ink Carta, and it produces a picture by electrifying microscopic particles roughly the width of a human hair.

E Ink screens are generally less prone to glare than traditional liquid crystal displays and much more power-efficient, but pose a challenge for touchscreen tablets like the ReMarkable because of their low refresh rate. That's where the ReMarkable is different.

Most E Ink screens take 100 milliseconds to refresh completely, which is fast enough for flipping pages in an ebook but too slow for real-time sketching and note-taking. ReMarkable's 1,872-by-1,404-pixel (226 dots per inch) Canvas display, in contrast, achieves a 55 millisecond response time.

So how does writing on the ReMarkable tablet actually feel? It's not quite like paper, but there's resistance and texture akin to a really thin sheet of notebook paper. That's thanks in part to the ReMarkable tablet's felt-tipped stylus, which has a marker tip custom-designed to mimic the feel of paper. (ReMarkable says it has more than 2,048 levels of pressure sensitivity and 512 levels of tilt.)

The felt tips don't last forever, though. ReMarkable sells replacement kits in packs of 10 for an undisclosed price, but warns that they could degrade in as little as six months. We didn't notice any serious wear after two weeks of light use, but it'll depend on how aggressively you sketch.

Disappointing performance and middling battery life

The pen's stellar performance stands in contrast to the rest of the experience, unfortunately.

The ReMarkable tablet suffers from the telltale limitations of E Ink technology: Tapping on a menu key or scroll wheel basically guarantees a delay and screen flashes while the tablet refreshes. It doesn't come close to the responsiveness of the stylus, and it's incredibly frustrating.

ReMarkable Tablet flat bottom

Kyle Wiggers/Digital Trends

The ReMarkable tablet's battery life is a little better than its performance, but it didn't last as long as I'd like. After a typical 9-to-5 day of jotting down reminders, organizing my to-do list, and absent-mindedly doodling, I could count on the 3,000mAh battery dipping well below 40 percent by midweek.

ReMarkable's engineers say they're targeting two weeks of standby time, which seems a little optimistic. But we'll have to take their word for it.

Software

Sketching on the ReMarkable takes place mostly in Notebook, the tablet's catchall for quick notes and doodles. In the default view, you get a nearly unlimited number of pages and a vast array of drawing tools.

I found the ReMarkable's basic tools to be the most useful.

The left-hand side is where you'll find different stylus types: A pencil, a pen, a brush, and a highlighter. Tap on one, and sub-menus for stroke thickness and color appear in the top-left corner. (You can choose between a ballpoint pen and a marker, for example, and a sharp pencil or a tilted pencil.) Other tools include the eraser, which lets you delete portions of drawings or the entire page; the magnifying glass, which lets you zoom in or out of the page; and a "minimalist" mode that hides the toolbars from view.

On a day-to-day basis, I found the ReMarkable's basic tools to be the most useful. The built-in move button saved me the trouble of having to erase and rewrite things I'd written, and the undo button made getting rid of mistakes as easy as the press of a button.

For folks more artistically inclined than myself, ReMarkable's notebook is chock-full of drawing aids. A Photoshop-like layering tool lets you add, remove, edit, and switch between backgrounds and foregrounds, and a gallery of templates provides premeasured grids and lines for sheet music, weekly schedules, and more. (ReMarkable says that users will eventually be able to create their own templates.)

Those features tie into the ReMarkable tablet's companion app for Android, iOS, and PC. When the tablet is connected to Wi-Fi, notebook pages sync automatically each time you make a change. Each app has a built-in viewer, and a handy export tool that lets you convert any sketchbook page into a PDF document or PNG image.

They work well enough, but documents didn't always sync right away in our testing. There's also an absence of support for third-party storage services like Dropbox and Google Drive (ReMarkable says it's working on this). And we couldn't get Live View, one of the ReMarkable tablet's most promising cross-platform features, working properly. It's supposed to show sketches on the PC or mobile app in real time, but neither the Android app nor the PC app acknowledged Live View when we enabled it on the tablet. (ReMarkable says it's aware of the bug.)

Availability

ReMarkable's crowdfunding campaign ended in August, but ReMarkable says it'll open its store for pre-orders later this year ahead of a spring 2018 release window. Those who pre-ordered earlier this year will get the ReMarkable in September 2017.

The ReMarkable tablet and stylus will cost $600. It comes with a folio cover, a USB cable, and 10 pen tips.

Warranty information

ReMarkable offers a limited one-year warranty that protects against manufacturing defects. If there's anything wrong with the tablet upon delivery, it'll offer a repair and/or replacement at no charge.

The warranty doesn't cover wear and tear, accidental damage, or "improper" modifications like reengineering or software modifications. In other words: If you drop the ReMarkable tablet on a hardwood floor, you're liable for the damage.

ReMarkable tablet Compared To Our Take

The ReMarkable tablet delivers on its promise of imitating pen and paper, but at a premium most people won't be happy paying.

Is there a better alternative?

It depends on whether you're willing to settle.

The ReMarkable tablet is the closest thing we've tried to paper, and its E Ink screen has a theoretical advantage when it comes to battery life. But as it stands, more conventional tablets are the better buy.

For $700 (plus the price of the Apple Pencil), Apple's iPad Pro 10.5 puts a wider array of drawing, note-taking, and general-purpose apps at your fingertips. And the $800 entry-level Surface Pro, while a little on the pricey side, runs full-blown Windows 10 and the millions of applications it supports.

How long will it last?

The ReMarkable tablet's future is a bit murky. The eponymous company behind it doesn't have a proven track record.

But the company is already planning software updates. ReMarkable has working prototypes of a handwriting recognition system that transcribes notes to written text, and it intends to enable live sharing of notes through web links in the first half of 2018. In late 2017, the company tells Digital Trends, it will begin development on a web app for notebook pages and a plug-in for apps like OneNote and Evernote.

It remains to be seen if ReMarkable will follow through on those promises, of course. But given its transparency with crowdfunding backers so far and its detailed support webpage, we're inclined to believe that the ReMarkable tablet will last well past its launch date.

Should you buy it?

The ReMarkable is a great idea that's in need of refinement.

There's no disputing its technological achievement. Simply put, there's nothing on the market like the ReMarkable's Canvas display.

But that's not enough to justify the $600 asking price. ReMarkable pitches the tablet as a "distraction-free" alternative to the iPad and Surface Pro, but it's almost a moot point. If you're willing to pony up a few extra dollars, you can pick up a much more capable tablet that might not feel like paper, but offers a much more robust ecosystem.

That's not to mention the ReMarkable tablet's worrisome number of bugs and missing features. There's no way to annotate existing documents or search the content of notes, for example. And features like USB file transfer remain inexplicably in "beta."

Perhaps a future, cheaper version of the ReMarkable tablet will live up to all of its promises. But this one doesn't.


Source: ReMarkable tablet review

Thursday, 14 September 2017

FOR IMMEDIATE RELEASE: Contec Global Group / AfriOne Provides Chibok Survivors With Tools For Financial and Technological Empowerment

Lagos, Nigeria – WEBWIRE – Thursday, September 14, 2017

As many academic calendars in Nigeria get underway, AfriOne, renowned developer of the first Nigerian-'In Country' produced smartphone, alongside its international conglomerate, Contec Global Group, have together announced at a Forum held in Lagos in tandem with Nigerian Vice President Osinbajo and select representatives from the Federal Government (FG) that the innovative enterprise will, in yet another milestone of public-private-partnership (PPP) driven achievement, be providing many of the surviving victims of the 'Chibok 200' with vital financial and educational resources such as tablets, smartphones, and laptop computers. All parties will be offering these tools to provide a modicum of financial and technological liberation to the Chibok survivors, both those who have returned safely and "…those who we still hold out hope for," stated Sahir Berry, Founder and Managing Director, AfriOne.  Through being equipped with an array of today wholly-necessary mobile t echnology, it is planned that the girls once kidnapped in 2014 from the Government Secondary School in Borno State (the latter translated in English to 'The Home of Peace') by the militant cabal Boko Haram, will be able to join classmates and colleagues in pursuing academic ambition and achievement through connectivity, restoring ties to their respective communities and families in the process. Sahir Berry continued that he "…is inspired by the strength of these girls and uplifted by their safe return home. This gift is ultimately about regaining a sense of security and control in their daily lives. AfriOne and Contec Global are delighted to contribute to the empowerment of the returned young women and to their re-integration in to society through the provision of our in-country-produced mobile technology". Sahir was joined by Federal Government representatives when meeting the survivors and at that time, made the announcement of the joint offering. Roheen Berry, Managi ng Director, Contec Global Group, added that "…with these gifts, we fulfill our mantra of 'AfriOne for Everyone'; the girls will be able to feel at ease, re-gain independence, and be able to pursue their individual goals and aspirations with autonomy, made possible here through the latest, greatest and proudly Nigerian technology." ***ENDS*** About AfriOne   AfriOne is the proud manufacturer of the first in-country produced Nigerian smartphone. Accomplished within its state of the art factories in Ilupeju, AfriOne provides advanced mobile technology such as tablets, smart-mobile tech and laptop computers to the public at affordable price-points, aiming to increase connectivity in-country and meet the rising demands of globalization. About Contec Global Group Contec Global Group is a family run, multinational enterprise providing technology-based solutions to everyday challenges. Specializing in innovation-driven business, Contec has a range of subsidiary enterprises that develop targeted products aimed to resolve the many unique regional challenges that come with globalization and its impetus of diversification. Operating in Africa, Asia, the Middle East and Europe, its solutions focus on sustainable development in the areas of biometric security, hospitality, vehicle manufacturing, agriculture, FinTech, mobile technology, ICT and power generation. Editor's Note: Media Inquiries for AfriOne and/or Contec Global can be forwarded to International Counsel, Mr. Sam Amsterdam of Amsterdam Group Public Relations Inc. - sam@AmsterdamGroup.net 

( Press Release Image: https://photos.webwire.com/prmedia/47230/213615/213615-1.jpg )

Related Links www.ContecGlobal.com www.AfriOne.com

WebWireID213615

   AfriOne  Contec Global  #BringBackOurGirls  Chibok  Nigeria Contact Information Sam Amsterdam Of Counsel Amsterdam Group Public Relations Inc. Sam@AmsterdamGroup.net

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.


Source: FOR IMMEDIATE RELEASE: Contec Global Group / AfriOne Provides Chibok Survivors With Tools For Financial and Technological Empowerment

Wednesday, 13 September 2017

Cisco : Press Release

AMSTERDAM, IBC, September 14, 2017 - Sky New Zealand, a leader in the New Zealand payTV market, is transforming its Pay TV operations with the Cisco Infinite Video Platform. Taking its entertainment service to new levels, Sky will introduce multiscreen TV experiences that will reach its New Zealand subscribers via their phones, tablets and Internet connected set-top boxes/receivers.

On the horizon is the introduction of a Hybrid PVR solution with Kaon Hybrid DVR set-top boxes and Video-on-Demand over IP, extending to iOS and Android personal consumer devices. This will be the beginning of a multi-phase technology transformation project that enables Sky to utilize cloud technologies for the network operations and video delivery side, as well as the consumer side with new services like multiscreen Cloud DVR.

'The New Zealand Pay TV market is witnessing a lot of different players introducing multiscreen and OTT services, while a large population is still watching TV via satellite dishes,' said Julian Wheeler, chief products & technology officer, Sky New Zealand. 'With our existing leadership position, Sky is uniquely positioned to bring these two segments together and offer a seamless experience that brings the best of the broadcast & IP world, and takes the TV experience to a whole new level. Cisco's cloud-based SaaS delivery model combining broadcast and IP offered us the speed we needed to get new services to market.'

'While the bulk of the premium video today is over broadcast networks, the world is rapidly moving toward a new normal, where the future of video will be the IP network,' said Conrad Clemson, senior vice president and general manager, Service Provider Platforms and Applications, Cisco. 'With the Infinite Video Platform, our vision is to make IP video match and exceed broadcast quality and reliability. Sky joins a growing global community of customers who are moving along with this vision.'

Cisco is building the simplified, automated, and virtualized network platform of the future based on industry-leading software, systems, silicon, and services. This enables service providers and media and web companies worldwide to reduce costs, speed time to market, help secure their networks, and sustain profitable growth.

Supporting Resources

RSS feed for Cisco: http://newsroom.cisco.com/dlls/rss.html

About Sky New ZealandSky Network Television Limited (branded as SKY) is the largest satellite Pay TV provider in New Zealand. The industry leading service is capable of reaching TV Viewers across New Zealand from Cape Reinga to the Bluff. Learn more at www.sky.co.nz

About CiscoCisco (NASDAQ: CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

# # #

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.


Source: Cisco : Press Release

Tuesday, 12 September 2017

ASRock release its X10 IoT router for smart homes

IoT is the future, not doubt about it. ASRock have taken the initiative and released their new smart home router, the X10. Featuring dual-band Wi-Fi with MU-MIMO and Beamforming support, ASRock have included tech savvy features such as ZigBee and IR blasters. This allows the X10 to control various smart devices to create a central hub for your home network.

 

 

ZigBee radio allows for compatible smart home appliances (sensors, lighting, heaters, security systems, etc.) using a 250 Kbit/s channel and enable users to read/control through the ASRock Router app for Apple iOS and Google Android. ASRock Router app is also capable of setting automated scenes, this means your router can have the lights turn off when you go to bed, or turn on your TV when you get up in the morning. This allows for users to have complete control over their smart devices in their home using only their phone or tablet.

 

 

The X10's IR blasters allow the router to control devices such as TVs or air conditioners. Unfortunately, the router must be in direct line of the device to allow for the IR signal to not be interrupted for this feature to work. Other features you can expect from your X10 is the ability to operate a private VPN server, parental controls and the impressive geofencing feature. This allows you the ability to have cameras and security systems turn on when you leave your house and turn on your lights when you return.

 

ASRock's X10 AC1300 2-in-1 IoT wireless router is available now at Newegg for $139.99


Source: ASRock release its X10 IoT router for smart homes

Monday, 11 September 2017

Beyond Tablet Giveaway

From Woman's Day

OFFICIAL RULES NO PURCHASE NECESSARY TO ENTER OR WIN. A PURCHASE OR PAYMENT OF ANY KIND WILL NOT INCREASE YOUR CHANCES OF WINNING.

1. WINNER SELECTION: Winners (individually and collectively, the "Winner") will be selected on or about 11/30/2017 in a random drawing from among all eligible entries received. Each sweepstakes is a different drawing that must be entered separately. All the sweepstakes in these Official Rules are individually and collectively the "Sweepstakes." In the event the Sponsor does not receive any eligible entries, the Sponsor has the right to cancel the Sweepstakes. Drawing will be conducted by Woman's Day, whose decisions are final. Odds of winning will depend upon the total number of eligible entries received for each sweepstakes. In the event Canadians are eligible to enter as specified in the Eligibility paragraph below, and if there is a Canadian Winner, the Winner will be required to correctly answer a mathematical skill testing question as a condition of receiving the prize. Important Notice: You may be charged for visiting the mobile website in accordance with the terms of your service agreement with your carrier. Please consult your wireless service provider regarding your pricing plan. You must use a Smartphone device to participate via your mobile phone. Not all mobile phone providers carry the necessary service to participate. Check your phone capabilities for specific Internet instruct ions. If your data usage exceeds what is allotted by your data plan, you could be subject to additional fees by your carrier. Please contact your mobile service provider with any questions regarding your bill.

2.WINNER NOTIFICATION: Winner will be notified within one (1) month of the last day of the Sweepstakes, via e-mail, and/or at Sponsor's discretion, via phone or postal mail. In the event the Winner doesn't respond to Sponsor's notification or does not accept the prize within five (5) business days of notification, the prize will be deemed forfeited and an alternate Winner will be selected. In the event that any one or more potential Winner(s) fails to respond as stated above, declines the prize or fails to provide signed affidavits or release s, such Winner(s) will be deemed to forfeit the prize and Sponsor will select an alternate Winner(s) from the remaining eligible entrants. If any alternate(s) similarly fails to respond or declines the prize, Sponsor will use a reasonable number of attempts, in its discretion, to award the prize(s) to another alternate(s) but if it is unable to do so, the prize(s) will be finally forfeited and Sponsor shall have no further liability in connection with said Sweepstakes. List of Winners: For the names of the Winners, send a separate self-addressed, stamped envelope to Woman's Day September Sweepstakes Winners' List, Hearst Communications, Inc., 300 West 57th Street NY, NY 10019 within two (2) months from the Winner notification date as specified above.

Beyond Tablet Sweepstakes: Enter beginning 12:01 a.m. (ET) on September 12, 2017, through 11:59 p.m. (ET) on November 12, 2017 (the "Entry Period"). Go to womansday.com/giveaways on a computer or wireless device and complete and submit the entry form pursuant to the onscreen instructions. PLEASE NOTE THAT YOUR ENTRY WILL NOT BE COMPLETED UNTIL YOU HAVE COMPLETED THE OFFICIAL ENTRY FORM AND ENTERED YOUR CONTACT INFORMATION. Prizes & Approximate Retail Value: One (1) winner will receive a Beyond Tablet with five (5) included games: Yes or No, Happy Circus, Happy Tunes, Play Do Re Mi, Tong Tong Cha (ARV: $200), plus seven (7) additional games: Music Cube (ARV: $40), Lost Pyramid (ARV: $40), Battle of Submarines (ARV: $50), Elemencery ($50), Funny Fruits ($20), Spot the Animal ($20), and Monster Crash ( $30). Total value of prize package: $450. Total ARV of all prizes awarded: $450. Any difference between the stated ARV and the actual value of the prize will not be awarded in any form.

3. ENTRIES: Limit one (1) entry per person per day for Sweepstakes. Multiple entries from the same person per day will be disqualified. Entries become the property of the Sponsor and will not be returned. Proof of submission does not constitute proof of receipt. If applicable, illegible, inaccurate, lost, late, misdirected, incomplete, mutilated, postage due or mechanicall y reproduced entry forms or entry forms that have been tampered with will be disqualified. Online entrants must have valid email address and it is entrant's responsibility to update Sponsor of any change in email address. The mobile phone number and wireless service provider/carrier of mobile entrants (if applicable) will be automatically captured in the Sweepstakes database and all participation will be limited to that phone number unless entrant notifies Sponsor of a change. If there is a dispute as to the identity of an online or mobile entrant, the prize will be awarded to the authorized account holder of the email address or mobile phone. The "authorized account holder" is defined as the natural person to whom the email address or mobile phone is assigned by an internet service provider, online service provider, carrier, mobile phone provider or other organization (e.g., business, educational institution, etc.) that is responsible for assigning the email addresses for the domai n associated with the submitted email address or responsible for assigning the mobile phone number.

Read More

4. ELIGIBILITY: Open to legal residents of the 50 United States and the District of Columbia, who are eighteen (18) years of age in their state or territory of residenc e at time of entry. Legal residents of Canada (excluding Quebec) who have reached the aforementioned age in their province of residence at time of entry are also eligible to enter. Void in Puerto Rico and where prohibited by law. Employees of Sponsor, its parents, affiliates and subsidiaries, participating advertising and promotion agencies, independent judging organizations, and prize suppliers (and members of their immediate family and/or those living in the same of household of each such employee) are not eligible.

5. CONDITIONS OF PARTICIPATION: Expenses not specifically included in prize description and all t axes are the sole responsibility of the Winner. Each prize is awarded "as is" with no warranty or guarantee, either express or implied outside of manufacturer's limited warranty. No transfer, assignment or substitution of a prize permitted, except Sponsor reserves the right to substitute prize for an item of equal or greater value in the event an advertised prize is unavailable. The Winner is required to comply with any and all applicable federal, state, provincial, if Canadians are eligible to enter, and local laws, rules and regulations. All federal, state and local taxes, and any other costs not specifically provided for in these Official Rules are solely the Winner's responsibility. If the actual retail value of any Winner's prize is $600 or more, the Winner must complete a W9 form and supply Sponsor with his/her social security number for tax purposes. An IRS Form 1099 will be issued in the name of the Winner for the actual value of the prizes received. Sponsor shall have no re sponsibility or obligation to the Winner or potential Winner who are unable or unavailable to accept or utilize prizes as described herein. Entrants agree to be bound by the terms of these Official Rules and by the decisions of Sponsor, which are final and binding on all matters pertaining to this Sweepstakes. Winner may be required to sign and return an Affidavit of Eligibility, a Liability Release and where legally permissible a Publicity Release within seven (7) days following the date of first attempted notification. Failure to comply with this deadline may result in forfeiture of the prize and selection of an alternate Winner. Return of any prize/prize notification as undeliverable may result in disqualification and selection of an alternate Winner. Winner hereby further agrees that it will sign any documents necessary to transfer copyright of his/her submitted entry, if applicable, to Sponsor within seven (7) days following the date of first attempted notification. By entering , Entrant grants permission for Sponsor, and any of its affiliates and subsidiaries, participating advertising and promotion agencies, and prize suppliers to use the entrant's submission (including an altered form of the entry), if any, for editorial, advertising and promotional purposes without additional compensation, unless prohibited by law. If images are being submitted to Sponsor as a requirement for entry, Entrants agree that they have all rights to use the images submitted and to allow Sponsor, any of its affiliates and subsidiaries, participating advertising and promotion agencies, and prize suppliers to reuse any of the images, without any liability, for editorial, advertising and promotional purposes. Additionally, acceptance of the prize by Winner constitutes permission for Sponsor and any affiliates and subsidiaries, participating advertising and promotion agencies, and prize suppliers to use Winner's name and/or likeness and biographical material for editorial, adverti sing and promotional purposes without additional compensation, unless prohibited by law. By accepting prize, Winner agrees to hold Sponsor, its advertising and promotion agencies and their respective parent companies, subsidiaries, affiliates, partners, representative agents, successors, assigns, officers, directors, and employees harmless for any injury or damage caused or claimed to be caused by participation in the Sweepstakes or acceptance or use of the prize. Sponsor is not responsible for any printing, typographical, mechanical or other error in the printing of the offer, administration of the Sweepstakes or in the announcement of the prize.

6. INTERNET/MOBILE: Sponsor is not responsible for electronic transmission errors resulting in omission, interruption, deletion, defect, delay in operations or transmission, theft or destruction or unauthorized access to or alterations of entry materials, or for technical, network, telephone equipment, electronic, computer, hardware or software malfunctions or limitations of any kind, or inaccurate transmissions of or failure to receive entry information by Sponsor or presenter on account of technical problems or traffic congestion on the Internet, at any Web site, or via the mobile phone or any combination thereof. If for any reason the Internet or mobile phone portion of the program is not capable of running as planned, including infection by computer virus, bugs, tampering, unauthorized intervention, fraud, technical failures, or any other causes which corrupt of affect the administration, security, fairness, integrity, or proper conduct of this Sweepstakes, Sponsor reserves the right at its sole discretion to cancel, terminate, modify or suspend the Sweepstakes. Sponsor reserves the right to select winners from eligible entries received as of the termination date. Sponsor further reserves the right to disqualify any individual who tampers with the entry process. Sponsor may prohibit an entrant from participating in the Sweepstakes if it determines that said entrant is attempting to undermine the legitimate operation of the Sweepstakes by cheating, hacking, deception or other unfair playing practices or intending to abuse, threaten or harass other entrants. Caution: Any attempt by a participant to deliberately damage any Web site or undermine the legitimate operation of the Sweepstakes is a violation of criminal and civil laws and should such an attempt be made, Sponsor reserves the right to seek damages from any such participant to the fullest extent of the law.

7. DISPUTES/CHOICE OF LAW: Except where prohibited, each entrant agrees that: (1) any and all disputes, claims and causes of action arising out of or connected with this or any prize awarded shall be resolved individually, without resort to any form of class action, and exclusively by state or federal courts situated in New York, NY, (2) any and all claims, judgments and awards shall be limited to actual out-of-pocket costs incurred, but in no event attorneys' fees; and (3) no punitive, incidental, special, consequential or other damages, including without limitation lost profits may be awarded (collectively, "Special Damages"), and (4) entrant hereby waives all rights to claim Special Damages and all rights to have such damages multiplied or increased. New York State law, without reference to New York's choice of law rules, governs the Sweepstakes and all aspects related thereto.

8. SPONSOR: The Sponsor of these Sweepstakes is Hearst Communications, Inc., 300 W. 57th Street, New York, NY 10019.

You Might Also Like


Source: Beyond Tablet Giveaway

Friday, 8 September 2017

Cotempla XR-ODT Available for Pediatric ADHD

Full nationwide market launch of Cotempla XR-ODT will occur in early October

Full nationwide market launch of Cotempla XR-ODT will occur in early October

Neos Therapeutics announced the availability of Cotempla XR-ODT (methylphenidate extended-release) for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6–17 years. The drug, approved in June 2017, marks the first methylphenidate extended-release orally-disintegrating tablet (ODT) for the treatment of ADHD in this population.

Cotempla XR-ODT contains methylphenidate, a central nervous system (CNS) stimulant. Its initial approval was based on Phase 3 clinical data that evaluated children in a laboratory classroom setting. Children who received Cotempla XR-ODT exhibited a statistically significant improvement in ADHD symptom control vs. those who received placebo averaged across the classroom day. There were no serious adverse events observed during the study. 

Cotempla XR-ODT is a Schedule II controlled substance and is supplied as 8.6mg, 17.3mg, and 25.9mg strength ODT in cartons containing 5 blister cards of 6 tablets each. Currently , Cotempla XR-ODT is available in certain markets and will be available nationwide in early October.


Source: Cotempla XR-ODT Available for Pediatric ADHD

Thursday, 7 September 2017

Cladribine Tablets Demonstrates Sustained Disease Control over Four Years with Maximum of Only 20 Days Oral Treatment

  • CLARITY Extension data published in the MS Journal shows 75 per cent of patients who received two annual short courses of cladribine tablets remained relapse free over four years
  • The majority of patients who experienced Grade 3 lymphopenia in years one and two recovered to Grade 0-1 by the end of the study
  • MISSISSAUGA, ON, Sept.

    7, 2017 /CNW/ - Merck KGaA, Darmstadt, Germany, a leading science and technology company (operating as EMD Serono in Canada), today announced the publication of the results of the CLARITY Extension study in Multiple Sclerosis Journal. The trial, an extension of the Phase III CLARITY study, demonstrated that treatment of patients with relapsing remitting multiple sclerosis (MS) with cladribine tablets for two years, followed by two years of treatment with placebo, had clinical benefits similar to those seen with four years of treatment with cladribine tablets with a low risk of severe lymphopenia.

    The CLARITY Extension study included 806 patients out of 1,184 patients who completed the CLARITY study. The CLARITY Extension study assessed several clinical efficacy endpoints including annualised relapse rate (ARR) and confirmed three-month Expanded Disability Status Scale (EDSS) progression. The proportion of patients who remained relapse-free at the end of four years was similar to the patients who received cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension (75.6%), and those who received cladribine tablets 3.5 mg/kg in both studies (81.2%). The proportion of patients who remained free of three-month EDSS progression was also similar between the treatment groups (72.4% vs 77.4%).

    "Today's publication further strengthens the evidence for the use of cladribine tablets in MS, demonstrating significant, durable benefits in patients not receiving active treatment after the two short courses," said Prof. Gavin Giovannoni, a lead investigator i n the CLARITY studies and Chair of Neurology, Barts and The London School of Medicine and Dentistry. "The data from this publication and other recent articles suggest that cladribine tablets selectively targets the adaptive immune system, particularly the B-cell compartment, and therefore allows the immune system to reconstitute while still preventing MS disease activity in the majority of treated patients."

    "The enduring benefits in patients who did not receive active treatment after the two short courses alleviate some safety concerns normally associated with continuous immunosuppression seen with other treatment options,'' said Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit at the Ottawa Hospital, Senior Scientist at The Ottawa Hospital Research Institute and investigator for the CLARITY study.

    The safety outcomes were comparable to those seen in CLARITY; adverse event rates were similar in patients who received cladribine tablets in CLARITY followed by placebo in CLARITY Extension, and those who received cladribine tablets in both studies. In CLARITY, patients with active relapsing–remitting multiple sclerosis were randomized to placebo or one of two cumulative doses of cladribine tablets (3.5 or 5.25 mg/kg body weight) for two years. In CLARITY Extension, patients were administered placebo or a cumulative dose of cladribine tablets 3.5 mg/kg body weight. In patients who received cladribine tablets 3.5 mg/kg in CLARITY and placebo in CLARITY Extension, the majority of those who experienced Grade >3 lymphopenia recovered to Grade 0-1 by the completion of CLARITY Extension. Most AEs were classified as mild or moderate. In the patient group receiving placebo in CLARITY Extension following cladribine tablets 3.5 mg/kg in CLARITY, 3.1 per cent of patients discontinued because of AEs. The most frequent AE in patients receiving cladribine tablets in the CLARITY Extension study was lymphopenia. The majority of lymphopenia events were classified as mild or moderate, and the majority of patients who experienced lymphopenia Grade ?3 actually experienced Grade 3 only. In CLARITY Extension, herpes zoster infections were most frequent in patients receiving the highest cumulative dose of cladribine tablets (4.8%), however the incidence of herpes zoster in all other treatment groups was similar irrespective of cumulative dose (1.1–2.0%).

    "Today's data add to the growing evidence for the use of cladribine tablets in patients with relapsing MS," said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck KGaA, Darmstadt, Germany. "At Merck KGaA, Darmstadt, Germany we are very excited about the difference cladribine tablets could make in the lives of patients with this debilitating condition."

    In August, the European Commission (EC) granted Marketing Authorization for cladribine tablets for the treatment of adults with highly active relapsing MS* in the 28 countries of the Europe an Union (EU) in addition to Norway, Liechtenstein and Iceland. Merck plans additional filings for regulatory approval in other countries, including the United States.

    * Defined as: patients with 1 relapse during the previous year and ? 1 T1 Gd+ lesion or ? 9 T2 lesions while on therapy with other DMDs; OR patients with ? 2 or more relapses in the previous year, whether on DMD treatment or not.

    CLARITY Extension Study DesignThe CLARITY Extension study involved 806 patients out of 1,184 patients from the CLARITY study, allowing assessment of the effects of two years' additional treatment with cladribine tablets beyond the two-year CLARITY regimen. Patients who received cladribine tablets 3.5 mg/kg or 5.25 mg/kg in the CLARITY study were randomised to receive either cladribine tablets 3.5 mg/kg or placebo in CLARITY Extension, and patients who received placebo in the original CLARITY study received cladribine tablets 3.5 mg/kg in CLARITY Extension.

    About Cladribine T ablets Cladribine tablets is approved in the European Union for the treatment of highly active relapsing multiple sclerosis* (RMS). Cladribine tablets is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). Cladribine tablets is currently under clinical investigation and not yet approved for the treatment for any use in the United States or Canada. In August 2017, the European Commission (EC) granted marketing authorization for cladribine tablets for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland.

    The clinical development program for cladribine tablets includes:

  • The CLARITY (cladribine tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients w ith RRMS.
  • The CLARITY extension study: a two-year Phase III placebo-controlled study following on from the CLARITY study, designed to evaluate the safety and efficacy of cladribine tablets over an extended administration for four years.
  • The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).
  • The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.
  • PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies) study: interim long-term follow-up data from the prospective registry, PREMIERE, to evaluate the safety and efficacy of cladribine tablets This includes more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and more than 10 years of observation in some patients.
  • About Multiple SclerosisMultiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

    About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany generated sales of € 15.0 billion in 66 countries.

    Founded in 1668, Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

    About EMD Serono, Canada EMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada wit h headquarters in Mississauga, Ontario.

    SOURCE EMD Inc.


    Source: Cladribine Tablets Demonstrates Sustained Disease Control over Four Years with Maximum of Only 20 Days Oral Treatment